Effects of intramyocardial pVEGF165 delivery on regional myocardial blood flow: Evidence for a spatial 'delivery-efficacy' mismatch

Gene Therapy

Volumn 11, Issue 16, 2004, Pages 1249-1255

  Radke, P W ^a   Heinl Green, A ^b   Frass, O M ^b   Griesenbach, U ^a   Ferrari, S ^a   Geddes, D M ^a   Alton, E W F W ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Klinik für Herz Thorax Gefässchirurgie   (Germany)

Author keywords

Animal study; Myocardial ischaemia; Vascular endothelial growth factor

Indexed keywords

CHLORAMPHENICOL ACETYLTRANSFERASE; PLASMID VECTOR; VASCULOTROPIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY CONSTRICTION; DRUG EFFICACY; FEMALE; GENE DELIVERY SYSTEM; GENETIC CODE; HEART MUSCLE; HEART MUSCLE BLOOD FLOW; HEART VENTRICLE SEPTUM; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; REST; SCORING SYSTEM; STRESS; SWINE; ANIMAL; BLOOD PRESSURE; CHRONIC DISEASE; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; GENE TRANSFER; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; HEART MUSCLE ISCHEMIA; HEART RATE; METHODOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMEROIDEA; ANIMALIA; SUIDAE;

ANIMALS; BLOOD PRESSURE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CHRONIC DISEASE; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART RATE; MYOCARDIAL ISCHEMIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWINE; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4444280874     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302296     Document Type: Article

References (22)

1. Mukherjee D et al. Direct myocardial revascularisation and angiogenesis - how many patients might be eligible? Am J Cardiol 1999; 84: 598-600.
2. Simons M et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. An expert panel summary. Circulation 2000; 102: e73-e86.
3. Losordo DW et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
4. Rosengart TK et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474.
5. Tio R et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999; 10: 2953-2960.
6. Mack CA et al. Biological bypass with use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998; 115: 168-177.
7. Lee LY et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000; 69: 14-24.
8. White FC, Carroll SM, Magnet A, Bloor CM. Coronary collateral development in swine after coronary artery occlusion. Circ Res 1992; 71: 1490-1500.
9. Fuchs S et al. Lack of correlation between angiographic grading of collateral and myocardial perfusion and function: implications for the assessment of angiogenic response. Cor Art Dis 2001; 12: 173-178.
10. 165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001; 37: 616-623.
11. Lopez JJ et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998; 40: 272-281.
12. Chu VF et al. Angiogenesis using transmyocardial revascularization: comparison of laser versus mechanical pnctures. Ann Thorac Surg 1999; 68: 301-307.
13. Saito T et al. Nitric oxide system in needle-induced transmyocardial revascularization. Ann Thorac Surg 2001; 72: 129-136.
14. Pearlman JD, Laham RJ, Simons M. Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation- preliminary study in pigs. Radiology 2000; 214: 801-807.
15. Laham RJ et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000; 36: 2132-2139.
16. Udelson JE et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic coronary artery disease. Circulation 2000; 102: 1605-1610.
17. Peterson GL. A simplification of the protein assay method of Lowry et al. Which is more generally applicable? Anal Biochem 1977; 83: 346-356.
18. Hughes GC et al. Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J Appl Physiol 2003; 94: 1689-1701.
19. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation 1986; 74: 469-476.
20. Harada K et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996; 270: H1791-H1802.
21. Reinhardt CP et al. Stable labeled microspheres to measure perfusion: validation of a neutron activation assay technique. Am J Physiol Heart Circ Physiol 2001; 280: H108-H116.
22. Lee ER et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer. Hum Gene Ther 1996; 7: 1701-1717.